Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Reich Kristian (Last) (First) (Middle) C/O MOONLAKE IMMUNOTHERAPEUTICS		Person*	2. Issuer Name and Ticker or Trading Symbol <u>MoonLake Immunotherapeutics</u> [MLTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
		(3. Date of Earliest Transaction (Month/Day/Year) 02/27/2024	X Officer (give title Other (specify below) below) Chief Scientific Officer
DORFSTRASSE 29(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting
ZUG	V8	6300	Dula 40h 5 4(a) Transaction Indiaction	Person
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication X Check this box to indicate that a transaction was made pursuan satisfy the affirmative defense conditions of Rule 10b5-1(c). Set	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Class A ordinary shares, par value \$0.0001 per share	02/27/2024		S ⁽¹⁾		29,491	D	\$55	2,957,483	Ι	See footnote. ⁽²⁾
Class A ordinary shares, par value \$0.0001 per share	02/27/2024		S ⁽¹⁾		29,431	D	\$55	70,071	D	
Class A ordinary shares, par value \$0.0001 per share	02/28/2024		S ⁽¹⁾		31,910	D	\$55	2,925,573	Ι	See footnote. ⁽²⁾
Class A ordinary shares, par value \$0.0001 per share	02/28/2024		S ⁽¹⁾		28,090	D	\$55	41,981	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration		Expiration Da	i. Date Exercisable and Expiration Date Month/Day/Year)		int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

2. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Development and the securities are associated as a security of the securities are associated as a security of the security o Beratungsgesellschaft mbH.

/s/ Matthias Bodenstedt,

02/29/2024

Attorney-in-fact for Kristian Reich

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See